Medicine

David Baldwin

MB BS DM FRCPsych

Primary position:
Professor of Psychiatry

Background

The University of Southampton

Professor Baldwin became Head of the Mental Health Group in 2008 and was awarded a Personal Chair in 2010. He trained in medicine at Charing Cross Hospital Medical School, London and then in psychiatry at St Mary's Hospital Medical School and the Maudsley Hospital, London.

Professor Baldwin leads a group that aims to improve clinical outcomes in patients with mood and anxiety disorders. This involves investigating the role of neurobiological and psychological factors in causing and maintaining illness; through improving trial design when evaluating efficacy and tolerability of treatment interventions; by assessing the effectiveness and acceptability of treatment interventions in wider clinical practice; through identifying more accurately those patient groups at particular risk of poor outcomes; and by offering a specialist clinical service to patients with chronic and treatment-resistant conditions.

He leads the Anxiety Disorders Research Network, an international multi-centre independent collaborative cross-disciplinary research grouping, with support from the European College of Neuropsychopharmacology (ECNP).

He is an Honorary Consultant Psychiatrist in Southern Health NHS Foundation Trust, where he leads the tertiary referral specialist service for patients with mood and anxiety disorders.

Qualifications

MB BS Medicine and Surgery, University of London 1984
DM University of Southampton 2004
MRCPsych 1988 and FRCPsych 2002

Appointments held

Lecturer in Psychiatry 1987-1988, St Mary’s Hospital Medical School

Clinical Research Fellow 1988-1990, St Mary’s Hospital Medical School

Honorary Senior Lecturer in Psychiatry, 1992-1994 Imperial College London

Senior Lecturer in Psychiatry 1994-2006, Southampton

Reader in Psychiatry 2006-2010, Southampton

Professor of Psychiatry 2010 onwards, Southampton

Professor David Baldwin's photo

Publications

The University of Southampton's electronic library (e-prints)

Article

Barton, S., Karner, C., Salih, F., Baldwin, D.S. and Edwards, S.J. (2014) Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. Health Technology Assessment, 18, (50), 1-60. (doi:10.3310/hta18500). (PMID:25110830).
Palazzo, M.C., Dell'Osso, B., Altamura, A.C., Stein, D.J. and Baldwin, D.S. (2014) Health literacy about pharmacological treatment in anxiety disorders: a systematic review. Human Psychopharmacology Clinical and Experimental, 29, (3), 211-215. (doi:10.1002/hup.2397).
Baldwin, D.S., Anderson, I.M., Nutt, D.J., Allgulander , C., Bandelow, B., den Boer, J.A., Christmas, D.M., Davies, S., Fineberg, N.A., Lidbetter , N., Malizia, A., McCrone, P., Nabarro, D., O’Neill, C., Scott, J., van der Wee, N. and Wittchen, H-U (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28, (5), 403-439. (doi:10.1177/0269881114525674).
Everitt, Hazel, McDermott, Lisa, Leydon, Geraldine, Yules, Harvey, Baldwin, David and Little, Paul (2014) GPs' management strategies for patients with insomnia: a survey and qualitative interview study. British Journal of General Practice, 64, (619), e112-e119. (doi:10.3399/bjgp14X677176).
Bolognesi, F., Baldwin, D.S. and Ruini, C. (2014) Psychological interventions in the treatment of generalized anxiety disorder: a structured review. Journal of Psychopathology , 20, 9-24.
Pinkney, V., Wickens, R., Bamford, S., Baldwin, D.S. and Garner, M. (2014) Defensive eye-blink startle responses in a human experimental model of anxiety. Journal of Psychopharmacology (In Press).
Ainsworth, B., Eddershaw, R., Meron, D., Baldwin, D.S. and Garner, M. (2013) The effect of focused attention and open monitoring meditation on attention network function in healthy volunteers. Psychiatry Research
Baldwin, D.S., Pallanti, S. and Zwanzger, P. (2013) Developing a European research network to address unmet needs in anxiety disorders. Neuroscience & Biobehavioral Reviews, 37, (10), part 1, 2312-2317. (doi:10.1016/j.neubiorev.2013.01.009). (PMID: 23313646).
Baldwin, D.S., Aitchison, K., Bateson , A., Curran, H.V., Davies, S., Leonard, B., Nutt, D.J., Stephens, D.N. and Wilson, S. (2013) Benzodiazepines: Risks and benefits. A reconsideration. Journal of Psychopharmacology, 27, (11), 967-971. (doi:10.1177/0269881113503509).
Stein, D.J., Rothbaum, B.O., Baldwin, D.S., Szumski, A., Pedersen, R. and Davidson, J.R.T. (2013) Factor analysis of posttraumatic stress disorder symptoms using data pooled from two venlafaxine extended-release clinical trials. Brain and Behavior , 3, (6), 738-746. (doi:10.1002/brb3.183).
Everitt, H., Baldwin, D.S., Mayers, A., Malizia, A.L. and Wilson, S.J. (2013) Antidepressants for insomnia (protocol). The Cochrane Library, 10, 1-10. (doi:10.1002/14651858.CD010753).
Baldwin, D.S. and Foong, T. (2013) Editorial. Antidepressant drugs and sexual dysfunction. The British Journal of Psychiatry, 202, (6), 396-397. (doi:10.1192/bjp.bp.112.110650 ). (PMID:23732933).
Pritchard, C., Mayers, A. and Baldwin, D.S. (2013) Changing patterns of neurological mortality in the ten major developed countries 1979-2010. Public Health, 127, (4), 357-368. (doi:10.1016/j.puhe.2012.12.018). (PMID:23601790).
Bartram, David J., Sinclair, Julia M. and Baldwin, David S. (2013) Further validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) in the UK veterinary profession: Rasch analysis. Quality of Life Research, 22, (2), 379-391. (doi:10.1007/s11136-012-0144-4). (PMID:22383106).
Sparshatt, A., McAllister Williams, R.H., Baldwin, D.S., Haddad, P.M., Bazire, S., Weston, E., Taylor, P. and Taylor, D. (2013) A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. Acta Psychiatrica Scandinavica, 128, (3), 203-211. (doi:10.1111/acps.12044).
Dell'Osso, B., Glick, I.D., Baldwin, D.S. and Altamura, A.C. (2013) Can long-term outcomes be improved by shortening the duration of untreated illness in psychiatric disorders? A conceptual framework. Psychopathology, 46, (1), 14-21. (doi:10.1159/000338608). (PMID:22890286).
Baldwin, D.S., Rafiq, R. and Talat, B. (2013) Overcoming barriers in the pharmacological treatment of anxiety disorders. Neuropsychiatry, 3, (1), 33-44. (doi:10.2217/npy.12.73).
Impey, B. and Baldwin, D.S. (2013) On 'cognitive dysfunction' as a novel target for antidepressant treatment. Human Psychopharmacology Clinical and Experimental, 28, (6), 535-537. (doi:10.1002/hup.2360).
Baldwin, D.S., Palazzo, M.C. and Masdrakis , V.G. (2013) Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants. Depression Research and Treatment, 2013, 256841. (doi:10.1155/2013/256841). (PMID:23431429).
Talat, B., Mayers, A. and Baldwin, D.S. (2013) Quality of case reports of adverse drug reactions with psychotropic drugs: a 25-year review. Human Psychopharmacology Clinical and Experimental, 28, (5), 413-420. (doi:10.1002/hup.2329).
Pasche, S., Garner, M., Baldwin, D.S. and Sinclair, J.M.A. (2013) “Craving”: exploring the components of the desires for alcohol questionnaire (DAQ) and the relation to the severity of alcohol problems. Journal of Studies on Alcohol and Drugs, 74, (6), 950-955.
Baldwin, D.S. and Nutt, D.J. (2012) Editorial. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. European Neuropsychopharmacology, 22, (12), 841-843. (doi:10.1016/j.euroneuro.2012.07.018).
Baldwin, D.S., Hansen, T. and Florea , I. (2012) Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Current Medical Research and Opinion, 28, (10), 1717-1724. (doi:10.1185/03007995.2012.725035). (PMID:22978748).
Garner, M.J., Attwood, A., Baldwin, D.S. and Munafo, M.R. (2012) Inhalation of 7.5% carbon dioxide increases alerting and orienting attention network function. Psychopharmacology, 223, (1), 67-73. (doi:10.1007/s00213-012-2690-4).
Baldwin, D.S., Loft, H. and Florea , I. (2012) Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. International Clinical Psychopharmacology, 27, (4), 197-207. (doi:10.1097/YIC.0b013e3283530ad7).
Davidson, Jonathan, Stein, Dan J., Rothbaum, Barbara O., Pedersen, Ron, Szumski, Annette and Baldwin, David S. (2012) Resilience as a predictor of treatment response in posttraumatic stress disorder patients treated with venlafaxine extended release or placebo. Journal of Psychopharmacology, 26, (6), 778-783. (doi:10.1177/0269881111413821). (PMID:21926426).
Hou, Ruihua and Baldwin, David S. (2012) A neuroimmunological perspective on anxiety disorders. Human Psychopharmacology Clinical and Experimental, 27, (1), 6-14. (doi:10.1002/hup.1259). (PMID:22213434).
Brandish, Emma and Baldwin, D.S. (2012) Anxiety disorders. [in special issue: Psychiatry] Medicine, 40, (11), part 1, 599-606. (doi:10.1016/j.mpmed.2012.08.017).
Garner, M., Attwood, A., Baldwin, D.S., James, A. and Munafo, M. (2011) Inhalation of 7.5% carbon dioxide increases threat processing in humans. Neuropsychopharmacology, 36, 1557-1662. (doi:10.1038/npp.2011.15).
Bartram, David J., Yadegarfar, Ghasem, Sinclair, Julia M.A. and Baldwin, David S. (2011) Validation of the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) as an overall indicator of population mental health and well-being in the UK veterinary profession. The Veterinary Journal, 187, (3), 397-398. (doi:10.1016/j.tvjl.2010.02.010 ). (PMID:20303305).
Garner, M., Clarke, G., Graystone, H. and Baldwin, D.S. (2011) Defensive startle response to emotional social cues in social anxiety. Psychiatry Research, 186, 150-152. (doi:10.1016/j.psychres.2010.07.055).
Sinclair, Julia M.A., Nausheen, Bina, Garner, Matthew J. and Baldwin, David S. (2010) Attentional biases in clinical populations with alcohol use disorders: is co-morbidity ignored? Human Psychopharmacology, 25, (7-8), 515-524. (doi:10.1002/hup.1153). (PMID:2132286).
Wood, T.B., Nausheen, B., Garner, M.J., Sinclair, J.M.A. and Baldwin, D.S. (2010) Attentional bias in a clinical population of patients with alcohol use disorders (AUD's): the influence of disorder severity and abstinence. Journal of Psychopharmacology, 24, supplement 3, A85-A85.
Sinclair, J.M.A., Nausheen, B., Wood, T.B., Garner, M.J. and Baldwin, D.S. (2010) Attentional biases in a clinical population of patients with alcohol use disorders (AUDs): the impact of comorbidity. Journal of Psychopharmacology, 24, supplement 3, A26-A26.
Hansen, Lars K., L'Allemand, Thomas, Thiry, Francine and Baldwin, David S. (2010) Structured relaxation in the treatment of akathisia: case series. Neuropsychiatric Disease and Treatment, 6, 269-271.
Bartram, D.J., Sinclair, J.M.A. and Baldwin, D.S. (2010) Interventions with potential to improve the mental health and wellbeing of UK veterinary surgeons. Veterinary Record, 166, (17), 518-523.
Williams, V.S.L., Edin, H.M., Hogue, S.L., Fehnel, S.E. and Baldwin, D.S. (2010) Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. Journal of Psychopharmacology, 24, (4), 489-496. (doi:10.1177/0269881109102779).
McAllister-Williams, R.H., Baldwin, D.S., Haddad, P.M. and Bazire, S. (2010) The use of antidepressants in clinical practice: focus on agomelatine. Human Psychopharmacology, 25, (2), 95-102. (doi:10.1002/hup.1094 ).
Dell'Osso, Bernardo, Buoli, Massimiliano, Baldwin, David S. and Altamura, A. Carlo (2010) Serotonin norepinephrine reuptake inhibitors in anxiety disorders: a comprehensive review of their clinical efficacy. Human Psychopharmacology, 25, (1), 17-29. (doi:10.1002/hup.1074 ).
Baldwin, D.S. and Lopes, A. (2010) Agomelatine in the treatment of mood and anxiety disorders. British Journal of Hospital Medicine, 71, (3), 153-156.
Hansen, L., L'Allemand, T., Thiry, F. and Baldwin, D.S. (2010) Structured relaxation in the treatment of akathisia associated with antipsychotic drug treatment of schizophrenia: case series. Neuropsychiatric Disease and Treatment (In Press).
Bartram, David J., Yadegarfar, Ghasem and Baldwin, David S. (2009) A cross-sectional study of mental health and well-being and their associations in the UK veterinary profession. Social Psychiatry and Psychiatric Epidemiology, 44, (12), 1075-1085. (doi:10.1007/s00127-009-0030-8).
Bartram, D.J., Yadegarfar, G. and Baldwin, D.S. (2009) Psychosocial working conditions and work-related stressors among UK veterinary surgeons. Occupational Medicine, 59, (5), 334-341. (doi:10.1093/occmed/kqp072 ).
Mayers, Andrew G., Grabau, Emma A.S., Campbell, Christine and Baldwin, David S. (2009) Subjective sleep, depression and anxiety: inter-relationships in a non-clinical group. Human Psychopharmacology: Clinical and Experimental, 24, (6), 495-501. (doi:10.1002/hup.1041 ).
Garner, Matthew, Möhler, Hanns, Stein, Dan J., Mueggler, Thomas and Baldwin, David S. (2009) Research in anxiety disorders: from the bench to the bedside. European Neuropsychopharmacology, 19, (6), 381-390. (doi:10.1016/j.euroneuro.2009.01.011).
Bartram, David, Sinclair, Julia M.A. and Baldwin, David S. (2009) Alcohol consumption among veterinary surgeons in the UK. Occupational Medicine, 59, (5), 323-326. (doi:10.1093/occmed/kqp060).
Kasper, Siegfried, Baldwin, David S., Lönn, Sara Larsson and Boulenger, Jean-Philippe (2009) Superiority of escitalopram to paroxetine in the treatment of depression. European Neuropsychopharmacology, 19, (4), 229-237. (doi:10.1016/j.euroneuro.2008.12.003 ).
Stein, D.J., Bandelow, B., Dolberg, O.T., Andersen, H.F. and Baldwin, D.S. (2009) Anxiety symptom severity and functional recovery or relapse. Annals of Clinical Psychiatry, 21, (2), 81-88.
Graystone, H.J., Garner, M.J. and Baldwin, D.S. (2009) Social anxiety symptoms across diagnoses among outpatients attending a tertiary care mood and anxiety disorders service. Journal of Affective Disorders, 114, (1-3), 305-309. (doi:10.1016/j.jad.2008.06.003).
Stein, Dan J., Pedersen, Ron, Rothbaum, Barbara O., Baldwin, David S., Ahmed, Saeeduddin, Musgnung, Jeff and Davidson, Jonathan (2009) Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis. International Journal of Neuropsychopharmacology, 12, (1), 23-31. (doi:10.1017/S1461145708008961).
Garner, M., Baldwin, D.S., Bradley, B.P. and Mogg, K. (2009) Impaired identification of fearful faces in Generalised Social Phobia. Journal of Affective Disorders, 115, (3), 460-465. (doi:10.1016/j.jad.2008.10.020).
Baldwin, David S. and Lopes, Antonio T.V. (2009) The influence of comorbid anxiety disorders on outcome in major depressive disorder. Medicographia, 31, (2), 126-131.
Baldwin, David S. and Lopes, Antonio T. (2009) Agomelatine improves symptoms of generalised anxiety disorder. Evidence-Based Mental Health, 12, (2), 54-54. (doi:10.1136/ebmh.12.2.54 ).
Morriss, Richard, Leese, Morven, Chatwin, Judy and Baldwin, David The THREAD Study Group (2008) Inter-rater reliability of the Hamilton Depression Rating Scale as a diagnostic and outcome measure of depression in primary care. Journal of Affective Disorders, 111, (2-3), 204-213. (doi:10.1016/j.jad.2008.02.013). (PMID:18374987).
Baldwin, D. S. (2008) Room for improvement in the pharmacological treatment of anxiety disorders. Current Pharmaceutical Design, 14, (33), 3482-3491. (doi:10.2174/138161208786848810).
Rothbaum, B.O., Davidson, J.R., Stein, D.J., Pedersen, R., Musgnung, J., Tian, X.W., Ahmed, S. and Baldwin, D.S. (2008) A pooled analysis of gender and trauma type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. Journal of Clinical Psychiatry, 69, (10), 1529-1539. (PMID:19192435).
Davidson, Jonathan, Baldwin, David S., Stein, Dan J., Pedersen, Ron, Ahmed, Saeed, Musnung, Jeff, Benattia, Isma and Rothbaum, Barbara O. (2008) Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale. International Clinical Psychopharmacology, 23, (5), 299-303. (doi:10.1097/YIC.0b013e32830c202d).
Baldwin, D.S., Brandish, E.K. and Meron, D. (2008) The overlap of obsessive-compulsive disorder and social phobia and its treatment. CNS spectrums, 13, (9 Suppl 14), 47-53.
Moller, Hans-Jürgen, Baldwin, D. S., Goodwin, G., Kasper, S., Okasha, A., Stein, D. J., Tandon, R. and Versiani, M. (2008) Do SSRIs or antidepressants in general increase suicidality? WPA section on pharmacopsychiatry: consensus statement. European Archives of Psychiatry and Clinical Neuroscience, 258, (Supplement 3), 3-23. (doi:10.1007/s00406-008-3002-1).
Baldwin, David, Moreno, Ricardo A. and Brilley, Mike (2008) Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human Psychopharmacology: Clinical and Experimental, 23, (6), 527-532. (doi:10.1002/hup.955).
Kosky, N. and Baldwin, D.S. (2008) Prescribing for unlicensed applications. European Neuropsychopharmacologyn, 18, (supp.4), s199. (doi:10.1016/S0924-977X(08)70224-4).
Baldwin, David S., Ajel, Khalil I. and Garner, Matthew J. (2008) Anxiety disorders. Medicine, 36, (8), 415-421. (doi:10.1016/j.mpmed.2008.05.002).
Kasper, S., Baldwin, D.S. and Boulenger, J.-P. (2008) Pooled analysis of two randomised clinical trials of escitalopram and paroxetine in the treatment of major depressive disorder. International Journal of Neuropsychopharmacology, 11, (S1), p.S192. (doi:10.1017/S1461145708009462).
Stein, Dan J., Baldwin, David S., Baldinetti, Francesca and Mandel, Francine (2008) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. European Neuropsychopharmacology, 18, (6), 422-430. (doi:10.1016/j.euroneuro.2008.01.004).
Bartram, David and Baldwin, David (2008) Mental health and wellbeing survey. Veterinary Record, 162, (26), p.868. (doi:10.1136/vr.162.26.868). (PMID:18587068).
Stein, D.J., Bandelow, B., Dolberg, O.T., Andersen, H.F. and Baldwin, D.S. (2008) How are symptom severity and functional recovery/relapse related? An analysis of the escitalopram database. European Psychiatry, 23, (Supplement 2), p.S369. (doi:10.1016/j.eurpsy.2008.01.1279).
Baldwin, D.S., Hou, R.H., Dolberg, O., Schellberg, S. and Hindmarch, I. (2008) Sleep and daytime psychomotor performance during acute and continuation treatment of major depressive disorder: double-blind randomised controlled trial of escitalopram vs paroxetine. Journal of Psychopharmacology, 22, (5), p.A43.
Bartram, D. J. and Baldwin, D. S. (2008) Veterinary surgeons and suicide: influences, opportunities and research directions. Veterinary Record, 162, (2), 36-40.
Ajel, K., Bhogal, K. and Baldwin, D. (2008) Prescribing of the antidepressant duloxetine: Can local clinical audit findings facilitate medicines management decisions? International Journal of Psychiatry in Clinical Practice, 12, (2), 156-159. (doi:10.1080/13651500701799052).
Rothbaum, Barbara O., Davidson, Jonathan R. T., Stein, Dan J., Pedersen, Ron, Musgnung, Jeff, Tian, Xiao Wei, Ahmed, Saeeduddin and Baldwin, David S. (2008) A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. Journal of Clinical Psychiatry, 69, (10), 1529-1539.
Baldwin, D.S., Bandelow, B., Dolberg, O.T., Andersen, H.F. and Stein, D.J. (2008) How are symptom severity and functional recovery/relapse related? African Journal of Psychiatry, 11, p.63.
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Moller, H. J., Zohar, J., Hollander, E., Kasper, S., Moller, H. J., Bandelow, B., Allgulander, C., Yuso-Gutierrez, J., Baldwin, D. S., Buenvicius, R., Cassano, G., Fineberg, N., Gabriels, L., Hindmarch, I., Kaiya, H., Klein, D. F., Lader, M., Lecrubier, Y., Lepine, J. P., Liebowitz, M. R., Lopez-Ibor, J. J., Marazziti, D., Miguel, E. C., Oh, K. S., Preter, M., Rupprecht, R., Sato, M., Starcevic, V., Stein, D. J., Van Ameringen, M. and Vega, J. (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. The World Journal of Biological Psychiatry, 9, (4), 248-312. (doi:10.1080/15622970802465807).
Baldwin, D.S., Stein, D.J., Dolberg, O.T. and Bandelow, B. (2008) How long should an initial treatment period be in anxiety disorders an in major depressive disorder? African Journal of Psychiatry, 11, p.63.
Baldwin, D.S., Garner, M.J., Clarke, G. and Graystone, H.J. (2008) Potentiated startle response to emotional expressions in social anxiety. Journal of Psychopharmacology, 22, (Supplement)
Baldwin, David, Hutchison, John, Donaldson, Kirsteen, Shaw, Bob and Smithers, Andrew (2008) Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670. Journal of Psychopharmacology, 22, (1), 55-63. (doi: 10.1177/0269881107078490).
Bartram, D. and Baldwin, D. (2008) Letter: Suicide by veterinary surgeons. Veterinary Record, 162, (11), 355-356.
Baldwin, David and Kasper, Siegfried (2008) Editorial. International Journal of Psychiatry in Clinical Practice, 12, (1), 3-4. (doi:10.1080/13651500801972898).
Lit, P., Garner, M.J., Carr, C. and Baldwin, D.S. (2008) Trauma, depression and resilience in mood disorder service outpatients. Journal of Psychopharmacology, 22, (Supplement), p.A77.
Walters, P., Bekoe, O.O., Sinclair, J.M.A. and Baldwin, D. S. (2008) Nicotine dependence in psychiatric inpatients undergoing alcohol or drug detoxification: minimal impact of a brief educational intervention. Journal of Psychopharmacology, 22, (Supplement)
Bartram, D.J., Yadegarfar, G. and Baldwin, D.S. (2008) Reported alcohol consumption, depressive and anxiety symptoms, and mental well-being among UK veterinary surgeons: cross-sectional questionnaire survey. Journal of Psychopharmacology, 22, (Supplement)
Bekoe, O.O., Walters, P., Baldwin, D.S. and Sinclair, J.M.A. (2008) Prevalence of substance abuse comorbidity in psychiatric inpatients and its impact on length of hospital admission. Journal of Psychopharmacology, 22, (Supplement)
Sartorius, Norman, Baghai, Thomas C., Baldwin, David S., Barrett, Barbara, Brand, Ursula, Fleischhacker, Wolfgang, Goodwin, Heinze, Knapp, Martin, Leonard, Brian E., Lieberman, Jeffrey, Nakane, Yoshibumi, Pinder, Roger M., Schatzberg, Alan F., Švestka, Jaromír, Baumann, Pierre, Ghalib, Kareem, Markowitz, John C., Padberg, Frank, Fink, Mank, Furukawa, Toshiaki, Fountoulakis, Konstantinos N., Jensen, Peter, Kanba, Shigenobu and Riecher-Rössler, Anita (2007) Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. International Journal of Neuropsychopharmacology, 10, (Supplement 1), S1-S121. (doi:10.1017/S1461145707008255).
Baldwin, David S. and Kosky, Nick (2007) Off-label prescribing in psychiatric practice. Advances in Psychiatric Treatment, 13, (6), 414-422. (doi:10.1192/apt.bp.107.004184).
Stein, D., Rothbaum, B.O., Baldwin, D.S., Tian, X.W., Pedersen, R., Ahmed, S. and Davidson, J.R.T. (2007) Poster sessions P.1.c.049. Symptoms of post-traumatic stress disorder: examination of factor structure in two separate clinical trials. European Neuropsychopharmacology, 17, (Supplement 4), S270-S271. (doi:10.1016/S0924-977X(07)70373-5).
Baldwin, D.S. (2007) Satellite symposia C.20.04. Anxiety disorders treated with an ASRI antidepressant. European Neuropsychopharmacology, 17, (Supplement 4), S611-S612. (doi:10.1016/S0924-977X(07)70977-X).
Sinclair, J., Garner, M.J. and Baldwin, D.S. (2007) Poster sessions P.6.e.005. Relationship between personality dimensions, substance misuse and repetition of deliberate self harm. European Neuropsychopharmacology, 17, (Supplement 4), S560-S561. (doi:10.1016/S0924-977X(07)70871-4).
Baldwin, D., Ajel, K. and Garner, M.J. (2007) Symposia S.21.02. Treatment-resistant generalized anxiety disorder. European Neuropsychopharmacology, 17, (Supplement 4), p.S208. (doi:10.1016/S0924-977X(07)70258-4).
Stein, D., Rothbaum, B.O., Baldwin, D.S., Tian, X.W., Pedersen, R., Ahmed, S. and Davidson, J.R.T. (2007) Symptoms of post-traumatic stress disorder: examination of factor structure in two seperate clinical trials. European Neuropsychopharmocology, 17, (Supplement 4), S270-S271. (doi:10.1016/S0924-977X(07)70373-5).
Angst, Jules, Gamma, Alex, Baldwin, David S., Ajdacic-Gross, Vladeta and Rössler, Wulf (2007) The generalised anxiety spectrum: prevalence, onset, course and outcome. European Archives of Psychiatry and Clinical Neuroscience (doi:10.1007/s00406-008-0832-9).
Bartram, David and Baldwin, David (2007) Letter. Mental health and wellbeing survey. Veterinary Record, 161, (10), p.360. (doi:10.1136/vr.161.10.360). (PMID:17827484).
Bandelow, B., Stein, D.J., Dolberg, O.T., Andersen, H.F. and Baldwin, D.S. (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry, 40, (4), 152-156.
Baldwin, David S. and Ajel, Khalil (2007) Development and evaluation of psychotropic drugs. Psychiatry, 6, (7), 279-283. (doi:10.1016/j.mppsy.2007.04.002).
Bhogal, Kuljit S. and Baldwin, David S. (2007) Pharmacological treatment of social phobia. Psychiatry, 6, 217-223. (doi:10.1016/j.mppsy.2007.02.007).
Baldwin, David (2007) Panic disorder and its comorbidity with Axis I and Axis II disorders. International Journal of Psychiatry in Clinical Practice, 11, (Supplement 1), p.S17. (doi:10.1080/13651500701322756).
Baldwin, David and Kasper, Siegfried (2007) Editorial. International Journal of Psychiatry in Clinical Practice, 11, (3), 169-170. (doi:10.1080/13651500701584017).
Baldwin, D.S. (2007) Importance of sleep disturbance in mood and anxiety disorders. International Journal of Psychiatry in Clinical Practice, 11, (4), 301-302. (doi:10.1080/13651500701745584).
Williams, V., Edin, H.M., Hogue, S.L., Fehnel, S.E. and Baldwin, D.S. (2007) Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. Journal of Psychopharmacology, 21, (Supplement), p.A39.
Garner, M.J., Littler, S., Mogg, K., Bradley, B.P. and Baldwin, D.S. (2007) Attentional bias for angry, fearful and happy facial expression in generalized social phobia. Journal of Psychopharmacology, 21, (supplement), p.A15.
Graystone, H.J., Garner, M.J. and Baldwin, D.S. (2007) Correlations between depressive and social anxiety symptoms across diagnoses among outpatients attending an NHS tertiary care specialist mood disorders service. Journal of Psychopharmacology, 21, (Supplement), p.A37.
Baldwin, D.S., Reines, E.H., Guiton, C. and Weiller, E. (2007) Escitalopram therapy for major depression and anxiety disorders. Annals of Pharmacotherapy, 41, (10), 1583-1592.
Baldwin, D.S., Guiton, C., Reines, E.H. and Weiller, E. (2007) Tolerability and safety of escitalopram [In: 'Abtracts' Oral Presentations p. 496]. Nordic Journal of Psychiatry, 61, (6), 486-502. (doi:10.1080/08039480701714778).
Montgomery, S.A., Baldwin, D.S., Blier, P., Fineberg, N.A., Kasper, S., Lader, M., Lam, R.W., Lepine, J.P., Moller, H.J., Nutt, D.J., Rouillon, F., Schatzberg, A.F. and Thase, M.E. (2007) Which antidepressants have demonstrated superior efficacy? A review of the evidence. International clinical psychopharmacology, 22, (6), 323-329.
Baldwin, David S. and Ajel, Khalil (2007) Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment, 3, (2), 185-191.
Baldwin, D.S., Montgomery, S.A., Nil, R. and Lader, M. (2007) Discontinuation symptoms in depression and anxiety disorders. International Journal of Neuropsychopharmacology, 10, (1), 73-84. (doi:10.1017/S1461145705006358).
Stein, D.J., Rothbaum, B.O., Baldwin, D.S., Tan, X.W., Ahmed, S., Musgnung, J., Pedersen, R. and Davidson, J. (2007) Onset of activity and time to response on individual CAPS-SX17 items in patients treated for posttraumatic stress disorder with venlafaxine XR: A pooled analysis. Depression and Anxiety, 24, (5), 367-367.
Stein, Dan J., Baldwin, David S., Dolberg, Ornah T., Despiegel, Nicolas and Bandelow, Borwin (2007) Letter to the Editor. Reply to More on Placebo Response by Jeffrey Allan Mattes. Journal of Clinical Psychiatry, 68, (12), 1984-1985.
Garner, M.J., Baldwin, D.S., Bradley, B. and Mogg, K. (2007) Impaired recognition of fearful faces in generalized social phobia. Journal of Psychopharmacology, 20, (Supplement), p.A26.
Ghosh, S., Arulrajan, A. and Baldwin, D.S. (2007) Unlicensed use of license psychotropic drugs in an intellectual disability service: cross-sectional case-note survey. Journal of Psychopharmacology, 21, (Supplement), p.A62.
Stein, Dan J., Ipser, Jonathan C., Baldwin, David S. and Bandelow, Borwin (2007) Treatment of obsessive-compulsive disorder. CNS Spectrums, 12, (2, Supplement 3), 28-35.
Baldwin, D.S. (2007) Room for improvement in the treatment of generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice, 11, (4), 309-309.
Baldwin, D.S. (2007) Depression and personality: conceptual and clinical challenges. British Journal of Psychiatry, 190, 541-542. (doi:10.1192/bjp.190.6.541).
Bartram, D. and Baldwin, D. (2007) Understanding depression - the 'black dog'. In Practice, 29, (10), 612-615.
Sinclair, J.M.A., Garner, M.J. and Baldwin, D.S. (2007) Relationship between personality dimensions, substance misuse and repetition of deliberate self harm. Journal of Psychopharmacology, 21, (Supplement), p.A33.
Bandelow, B., Stein, D.J., Dolberg, O.C., Andersen, H.F. and Baldwin, D.S. (2006) Improvement of quality of life in panic disorder with escitalopram versus citalopram, and placebo. International Journal of Psychiatry in Clinical Practice, 10, (4), p.322. (doi:10.1080/13651500601027547).
Baldwin, David S. (2006) Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes? CNS Spectrums, 11, (10), supplement 12, 34-39.
Davidson, Jonathan, Baldwin, David, Stein, Dan J., Kuper, Enrique, Benattia, Isma, Ahmed, Saeed, Pedersen, Ron and Musgnung, Jeff (2006) Treatment of post-traumatic stress disorder with venlafaxine extended release: a 6-month, randomized, controlled trial. Archives of General Psychiatry, 63, (10), 1158-1165. (doi:10.1001/archpsyc.63.10.1158).
Baldwin, David S., Huusom, Anna Karina Trap and Mæhlum, Eli (2006) Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. British Journal of Psychiatry, 189, (3), 264-272. (doi:10.1192/bjp.bp.105.012799).
Baldwin, David and Kasper, Siegfried (2006) Editorial. International Journal of Psychiatry in Clinical Practice, 10, (3), 153. (doi:10.1080/13651500600949709).
Lecrubier, Y., Weiller, E., Andersen, H. and Baldwin, D. (2006) Qualitative changes in symptomatology before and after treatment to remission in generalised anxiety disorder and major depression. International Journal of Neuropsychopharmacology, 9, (Supplement 1), p.S232. (doi:10.1017/S1461145706007292).
Nutt, David J., Baldwin, David S., Clayton, Anita H., Elgie, Rodney, Lecrubier, Yves, Montejo, Angel L., Papakostas, George I., Souery, Daniel, Trivedi, Madhukar H. and Tylee, Andre (2006) Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 67, (Suppl-6), 46-49.
Kendrick, Tony, Peveler, Robert, Longworth, Louise, Baldwin, David, Moore, Michael, Chatwin, Judy, Thornett, Andrew, Goddard, Jonathan, Campbell, Michael, Smith, Helen, Buxton, Martin and Thompson, Christopher (2006) Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. British Journal of Psychiatry, 188, (4), 337-345. (doi:10.1192/bjp.188.4.337).
Mayers, Andrew G. and Baldwin, David S. (2006) The relationship between sleep disturbance and depression. International Journal of Psychiatry in Clinical Practice, 10, (1), 2-16. (doi:10.1080/13651500500328087).
Williams, V.S.L., Baldwin, D.S., Hogue, S., Fehnel, S.E., Hollis, K. and Edin, H.M. (2006) Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. Journal of Clinical Psychiatry, 67, (2), 204-210.
Kasper, S. and Baldwin, D. (2006) Editorial. International Journal of Psychiatry in Clinical Practice, 10, (4), 233-234. (doi:10.1080/13651500601066875).
Baldwin, D.S. (2006) The importance of long-term tolerability in achieving recovery. International Journal of Psychiatry in Clinical Practice, 10, (Supplement 1), 31-37. (doi:10.1080/13651500600552552).
Bandelow, B., Baldwin, D.S., Dolberg, O.C., Andersen, H.F. and Stein, D.J. (2006) Comparison of the standard scales and CGI scores in major depressive disorder, panic disorder, social anxiety disorder and generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice, 10, 322-323.
Baldwin, D.S. and Papakostas, G.I. (2006) Symptoms of fatigue and sleepiness in major depressive disorder. Journal of Clinical Psychiatry, 67, (Supplement 6), 9-15.
Stein, Dan J., Baldwin, David S., Dolberg, Ornah T., Despiegel, Nicolas and Bandelow, Borwin (2006) Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. Journal of Clinical Psychiatry, 67, (11), 1741-1746.
Garner, M.J., Baldwin, D.S., Bradley, B.P. and Mogg, K. (2006) P.4.a Anxiety disorders and anxiolytics - Anxiety disorders (clinical), P.4.a.017. Impaired recognition of fearful faces in generalized social phobia. European Neuropsychopharmacology, 16, (Supplement 4), p.S457. (doi:10.1016/S0924-977X(06)70598-3).
Stein, D.J., Baldwin, D.S., Dolberg, O., Despiegel, N. and Bandelow, B. (2006) P.4.d Anxiety disorders and anxiolytics - Anxiolytics (basic), P.4.d.002. Which factors predict placebo response in anxiety disorders and major depression? European Neuropsychopharmacology, 16, (Supplement 4), p.S468. (doi:10.1016/S0924-977X(06)70618-6).
Bandelow, B., Baldwin, D.S., Dolberg, O.T., Andersen, H.F. and Stein, D.J. (2006) What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? Journal of Clinical Psychiatry, 67, (9), 1428-1434.
Bhogal, Kuljit, Baldwin, David L., Hartland, Louise and Nair, Rajesh (2006) Brief communication: differences between ethnic groups in demographic and clinical features of patients admitted and assessed after deliberate self-harm: a retrospective case-note study. International Journal of Social Psychiatry, 52, (6), 483-486. (doi:10.1177/0020764006066825).
Baldwin, D.S. (2006) Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders. International Journal of Psychiatry in Clinical Practice, 10, (Supplement 2), 12-15. (doi:10.1080/13651500600637056).
Nutt, David J., Baldwin, David S., Clayton, Anita H., Elgie, Rodney, Lecrubier, Yves, Montejo, Angel L., Papakostas, George I., Souery, Daniel, Trivedi, Madhukar H. and Tylee, Andre (2006) The role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 67, (Supplement 6), 46-49.
Tyrer, P. and Baldwin, D. (2006) Generalised anxiety disorder. Lancet, 368, (9553), 2156-2166. (doi:10.1016/S0140-6736(06)69865-6).
Baldwin, David, Bridgman, Kevin and Buis, Christel (2006) Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology, 20, (1), 91-96. (doi:10.1177/0269881105056666).
Jorgensen, T.R., Stein, D.J., Despiegel, N., Drost, P.B., Hernels, M.E.H. and Baldwin, D.S. (2006) Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. Annals of Pharmacotherapy, 40, (10), 1752-1758. (doi:10.1345/aph.1H156).
Bhogal, K., Baldwin, D.S.L. and Nair, R. (2006) Differences between ethnic groups in demographic and clinical features of patients admitted and assessed after deliberate self-harm. International Journal of Social Psychiatry
Baldwin, David S., Anderson, Ian M., Nutt, David J., Bandelow, Borwin, Bond, A., Davidson, Jonathan R.T., den Boer, J.A., Fineberg, Naomi A., Knapp, Martin, Scott, J. and Wittchen, H.-U. (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 19, (6), 567-596. (doi:10.1177/0269881105059253).
Baldwin, David (2005) Short-term treatment with hypnotic drugs for insomnia: going beyond the evidence. Journal of Psychopharmacology, 19, (2), 134-135.
Baldwin, D.S., Montgomery, S.A., Nil, R. and Lader, M. (2005) Discontinuation symptoms in social anxiety disorder, generalised anxiety disorder, and major depressive disorder. European Neuropsychopharmocology, 15, (Supplement 3), S425-S426.
Baldwin, D., Montgomery, S., Nil, R. and Lader, M. (2005) Symposia P.2.078. Discontinuation symptoms in social anxiety disorder, general anxiety disorder, and major depressive disorder. European Neuropsychopharmacology, 15, (Supplement 3), S425-S426. (doi:10.1016/S0924-977X(05)80867-3).
Baldwin, David S. and Polkinghorn, Claire (2005) Evidence-based pharmacotherapy of Generalized Anxiety Disorder. The International Journal of Neuropsychopharmacology, 8, (2), 293-302. (doi:10.1017/S1461145704004870).
Mayers, Andrew G. and Baldwin, David S. (2005) Antidepressants and their effect on sleep. Human Psychopharmacology, 20, (8), 533-559. (doi:10.1002/hup.726).
Baldwin, David S., Huusom, Anna K. Trap and Maehlum, Eli (2005) Escitalopram in the treatment of generalised anxiety disorder. World Journal of Biological Psychiatry, 6, (Supplement 1), p.S289.
Garner, M.J., Rutherford, D., Baldwin, D. S., Bradley, B. P. and Mogg, K. (2005) Attentional bias for facial expressions in generalized social phobia: an eye-movement study. Journal of Psychopharmacology, 19, (Supplement), p.A16.
Musgung, J., Davidson, J.R.T., Baldwin, D.S., Stein, D.J., Kuper, E., Benattia, I., Ahmed, S., Yan, B. and Pedersen, R. (2005) Venlafaxine XR in the treatment of PTSD: a 24-week randomized trial. World Journal of Biological Psychiatry, 6, (supplement 1), p.S303.
Baldwin, D. (2005) Symposia S.09.02. Treatment of panic disorder with and without agoraphobia. European Neuropsychopharmacology, 15, (Supplement 3), p.S328. (doi:10.1016/S0924-977X(05)80625-X).
Davidson, J., Baldwin, D.S., Stein, D.J., Kuper, E., Benattia, I., Ahmed, S., Yan, B., Pedersen, R. and Musgnung, J. (2005) A 6-month study of venlafaxine XR versus placebo in the treatment of posttraumatic stress disorder. European Neuropsychopharmocology, 15, (Supplement 3), p.S545. (doi:10.1016/S0924-977X(05)81140-X).
Sinclair, Julia M.A., Harriss, Louise, Baldwin, David S. and King, Elizabeth A. (2005) Suicide in depressive disorders: a retrospective case-control study of 127 suicides. Journal of Affective Disorders, 87, (1), 107-113. (doi:10.1016/j.jad.2005.03.001).
Baldwin, David S. and Nair, Rajesh V. (2005) Escitalopram in the treatment of generalized anxiety disorder. Expert Review of Neurotherapeutics, 5, (4), 443-449. (doi:10.1586/14737175.5.4.443).
Baldwin, David (2005) Easing the burden of panic disorder: comorbidity, diagnosis, and implications for treatment. CNS Spectrums, 9, (Supplement 12), 5-11.
Baldwin, D.S. (2005) Generalized anxiety disorder: what is the optimal treatment duration? [in special issue: 18th ECNP Congress] European Neuropsychopharmacology, 15, supplement 3, S655-S656. (doi:10.1016/S0924-977X(05)81391-4).
Baldwin, D.S., Montgomery, S.A., Nil, R. and Lader, M. (2005) Discontinuation symptoms in affective disorders. World Journal of Biological Psychiatry, 6, (Supplement 1), 190-191.
Peveler, Robert, Kendrick, Tony, Buxton, Martin, Campbell, Mike, Baldwin, David, Moore, Mike, Longworth, Louise, Smith, Helen, Goddard, Jonathan and Chatwin, Judy (2004) Randomised controlled trial to assess the health economics of antidepressants in primary care (The AHEAD Study). Journal of Affective Disorders, 78, (Supplement 1), S42-S43. (doi:10.1016/j.jad.2003.12.004).
Baldwin, David S. (2004) Sexual dysfunction associated with antidepressant drugs. Expert Opinion on Drug Safety, 3, (5), 457-470. (doi:10.1517/14740338.3.5.457).
Sinclair, Julia M.A., Mullee, Mark A., King, Elizabeth A. and Baldwin, David S. (2004) Suicide in schizophrenia: a retrospective case-control study of 51 suicides. Schizophrenia Bulletin, 30, (4), 803-811. (PMID:15954192).
Mogg, Karin, Baldwin, David S., Brodrick, Paul and Bradley, Brendan P. (2004) Effect of short-term SSRI treatment on cognitive bias in generalised anxiety disorder. Psychopharmacology, 176, (3-4), 466-470. (doi:10.1007/s00213-004-1902-y).
Tabiner, Melody, Youings, Sheila, Dennis, Nicholas, Baldwin, David, Buis, Christel, Mayers, Andrew, Jacobs, Patricia A. and Crolla, John A. (2003) Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines. American Journal of Human Genetics, 72, (3), 535-538. (doi:10.1086/367777).
Mayers, A.G., Baldwin, D.S., Dyson, R., Middleton, R.W. and Mustapha, A. (2003) Use of St John's wort (Hypericum perforatum L) in members of a depression self-help organisation: a 12-week open prospective pilot study using the HADS scale. Primary Care Psychiatry, 9, (1), 15-20. (doi:10.1185/135525703125002342).
Mayers, Andrew G., van Hooff, Johanna C. and Baldwin, David S. (2003) Assessing subjective sleep reports in the first-degree relatives of antidepressant-treated depressed outpatients. Human Psychopharmacology: Clinical and Experimental, 18, (3), 207-214. (doi:10.1002/hup.475).
Cole, M., Baldwin, D.S. and Thomas, P. (2003) Sex and segregation: staff attitudes explored. International Journal of Psychiatry in Clinical Practice, 7, (4), 243-247. (doi:10.1080/13651500310002364).
Dyson, R., Baldwin, D.S., Mayers, A.G., Tiernan, A. and Jenkins, G. (2003) The reported use and effectiveness of Hypericum (St John's wort) on affective symptoms in a depression self-help group. Primary Care Psychiatry, 8, (3), 99-102. (doi:10.1185/135525702125001137).
Mayers, Andrew G., VanHooff, Johanna C. and Baldwin, David S. (2003) Quantifying subjective assessment of sleep and life-quality in antidepressant-treated depressed patients. Human Psychopharmacology, 18, (1), 21-27. (doi:10.1002/hup.438).
Baldwin, David and Mayers, Andrew (2003) Sexual side-effects of antidepressant and antipsychotic drugs. Advances in Psychiatric Treatment, 9, 202-210.
Cole, M., Baldwin, D.S. and Thomas, P. (2003) Sexual assault on wards. Staff actions and reactions. Journal of Psychiatry in Clinical Practice, 7, (4), 239-242. (doi:10.1080/13651500310002355).
Pritchard, C. and Baldwin, D.S. (2002) Elderly suicide rates in Asian and English-speaking countries. Acta Psychiatrica Scandinavica, 105, (4), 271-275. (doi:10.1034/j.1600-0447.2002.1014.x).
Patel, Anita, Knapp, Martin, Henderson, Juliet and Baldwin, David (2002) The economic consequences of social phobia. Journal of Affective Disorders, 68, (2-3), 221-233. (doi:10.1016/S0165-0327(00)00323-2).
Montgomery, S.A., Baldwin, D.S. and Riley, A. (2002) Antidepressent medications: a review of the evidence for drug-induced sexual dysfunction. Journal of Affective Disorders, 69, (1-3), 119-140. (doi:10.1016/S0165-0327(01)00313-5).
Baldwin, David S. (2002) Escitalopram: efficacy and tolerability in the treatment of depression. Hospital Medicine, 63, (11), 668-671.
Grunze, H., Kasper, S., Goodwin, G., Bowden, C., Baldwin, D.S., Licht, R., Vieta, E. and Moller, H-J. (2002) WFSB task force on treatment guidelines for bipolar disorders. Part 1: treatment of bipolar depression. The World Journal of Biological Psychiatry, 3, (3), 115-124.
Baldwin, D.S., Evans, D.L., Hirschfeld, R.M. and Kasper, S. (2002) Can we distinguish anxiety from depression? Psychopharmacology Bulletin, 36, (Suppl 2), 158-165.
Baldwin, David S. (2001) Unmet needs in the pharmacological management of depression. Human Psychopharmacology, 16, (S2), S93-S99. (doi:10.1002/hup.337).
King, Elizabeth A., Baldwin, David S., Sinclair, Julia M.A., Baker, Nigel G., Campbell, Michael J. and Thompson, Chris (2001) The Wessex Recent In-Patient Suicide Study, 1. Case-control study of 234 recently discharged psychiatric patient suicides. British Journal of Psychiatry, 178, (6), 531-536. (PMID:11388969).
Baldwin, David S., Hawley, Christopher J. and Mellors, Karen (2001) A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. Journal of Psychopharmacology, 15, (3), 161-165.
Baldwin, David S. (2001) Depression and sexual dysfunction. British Medical Bulletin, 57, 81-99.
King, Elizabeth A., Baldwin, David S., Sinclair, Julia M.A. and Campbell, Michael J. (2001) The Wessex Recent In-Patient Suicide Study, 2. Case-control study of 59 in-patient suicides. British Journal of Psychiatry, 178, (6), 537-542.
Sinclair, J.M.A., Birtwistle, J. and Baldwin, D.S. (1998) The tolerability of venlafaxine. Reviews in Contemporary Pharmacotherapy, 9, (5), 333-344.

Book

Montgomery, Stuart A. and Baldwin, David S. (2006) Clinicians manual on generalized anxiety disorder, London, UK, Current Medicine Group, 63pp.

Book Section

Hou, R.H., Tang, Zhen and Baldwin, D.S. (2013) Potential neuroimmunological targets in the treatment of anxiety disorders. In, Baldwin, D.S. and Leonard, B.E. (eds.) Anxiety Disorders. Basel, CH, Karger, 67-84. (Modern Trends in Pharmacopsychiatry, 29). (doi:10.1159/000351965).
Baldwin, D.S., Ajel, K. and Garner, M. (2009) Pharmacological treatment of Generalised Anxiety Disorder. In, Steckler, T. and Stein, M.B. (eds.) Behavioral Neurobiology of Anxiety and its Treatment. , Springer.
Baldwin, David S. and Garner, Matthew J. (2008) How effective are current drug treatments for anxiety disorders, and how could they be improved? In, Blanchard, Robert, Blanchard, D. Caroline, Griebel, Guy and Nutt, David (eds.) Handbook of Anxiety and Fear. Amsterdam, The Netherlands, Elsevier, 395-411. (Handbook of Behavioral Neuroscience, 17). (doi:10.1016/S1569-7339(07)00001).
Tyrer, Peter and Baldwin, David (2008) Treatment of generalized anxiety and somatoform disorders. In, Tyrer, Peter and Silk, Kenneth R. (eds.) Cambridge Textbook of Effective Treatments in Psychiatry. Cambridge, GB, Cambridge University Press, 527-541.
Baldwin, David S. (2007) How to work with the media - and survive. In, Bhugra, Dinesh, Bell, Stuart and Burns, Alistair (eds.) Management for Psychiatrists. Third edition. London, UK, RCPsych Publications, 411-418.
Baldwin, D.S. (2007) Nuevas lineas de tratamiento farmacologico delos trastornos de ansiedad (New approaches to the pharmacological treatment of anxiety disorders). In, Vázquez-Barquero, José Luis, Jesús Artal, Simón and Crespo-Facorro, Crespo (eds.) Las Fases Iniciales De Las Enfermedades Mentales: Trastornos Bipolares. Barcelona, Spain, Masson.
Baldwin, D.S. (2006) A doctor's view. In, Wield, Cathy (ed.) Life after Darkness: A Doctor's Journey Through Severe Depression. Oxford, UK, Radcliffe, 203-205.
Baldwin, David S. and Polkinghorn, Claire (2005) Evidence-based pharmacotherapy of generalized anxiety disorder. In, Stein, Dan J., Lerer, Bernard and Stahl, Stephen (eds.) Evidence-based Psychopharmacology. Cambridge, UK, Cambridge University Press, 88-104. (doi:10.2277/0521531888).
Baldwin, D.S. (2000) Affective disorders. In, Gregoire, Alain (ed.) Adult Severe Mental Illness. London, UK, Greenwich Medical Media, 33-52.
Baldwin, David S. and Sinclair, Julia M.A. (1997) Recurrent brief depression: 'nasty, brutish and short'. In, Bhugra, Dinesh and Munro, A. (eds.) Troublesome Disguises: Underdiagnosed Psychiatric Syndromes. Oxford, GB, Blackwell Science, 226-240.

Monograph

Barton, Samantha, Karner, Charlotta, Salih, Fatima, Baldwin, David and Edwards, Steven (2014) Clinical effectiveness of interventions for treatment-resistant anxiety in older people; a systematic review. Southampton, GB, NIHR Journals Library, 86pp. (Health Technology Assessment, (doi:10.3310/hta18500) , 18:50).
Peveler, R., Kendrick, A., Buxton, M., Longworth, L., Baldwin, D., Moore, M., Chatwin, J., Goddard, J., Thornett, A., Smith, H., Campbell, M. and Thompson, C. NCCHTA (2005) A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Southampton, UK, National Coordinating Centre for Health Technology Assessments, 152pp. (Health Technology Assessment, (Vol 9: number 16) ).
 

Research

Research Interests

Investigating the role of neurobiological and psychological factors in causing and maintaining illness

This includes investigations of attentional and interpretative biases in patients with anxiety disorders, before and after pharmacological treatment, and by conducting similar studies in first-degree relatives and healthy controls, designed to reveal endophenotypes for anxiety disorders. A similar approach is used to explore neuropsychological factors in causing and maintaining sleep disorders.

Improving trial design when evaluating efficacy and tolerability of treatment interventions

I work in partnership with pharmaceutical and biotechnology companies, through the University Research and Enterprise service, to refine the design of randomised controlled trials and facilitate development of improved psychotropic drugs. This has led to better understanding of the relative efficacy and safety of antidepressant and anxiolytic drugs, and of the mechanisms underlying antidepressant-associated sexual dysfunction, and then relationship between an early onset of clinical effect and the likelihood of responding to pharmacological treatment.

Assessing the effectiveness and acceptability of treatment interventions in wider clinical practice

Current collaborative studies include an evaluation of clinical and cost-effectiveness of antidepressant drugs in the treatment of negative symptoms of schizophrenia, and an investigation of the effects of mindfulness-based cognitive therapy in patients with highly recurrent unipolar depressive disorder and persistent mild depressive symptoms.

Identifying more accurately those patient groups at particular risk of poor outcomes

This includes identification of demographic and clinical factors associated with completed suicide after discharge from psychiatric inpatient care. Current research into attempted and completed suicide includes an investigation of suicides on the island of Jersey between 2000 and 2009.

Leading the Anxiety Disorders Research Network

This is an international multi-centre independent collaborative cross-disciplinary research grouping, with support from the ECNP. It currently includes 22 research groups in 16 centres across 10 countries, and aims to address currently unmet needs in anxiety and related disorders. This is achieved by harmonising research and clinical databases and refining research methodologies; by evaluating innovative interventions, particularly in previously neglected patient groups; and by building a platform for pragmatic randomised controlled effectiveness trials. 10 of the ADRN centres are involved in the European and South African Research Network in Anxiety Disorders (EUSARNAD) programme which I coordinate. The EUSARNAD is supported by the Marie Curie Actions (People) International Research Staff Exchange Scheme (PIRES-GA2010-269213).

Offering a specialist clinical research-lead service to patients with chronic and treatment-resistant conditions

Patients with mood and anxiety disorders are referred by secondary care services, across the south of England. Approximately 50% have recurrent unipolar depressive disorder, 25% bipolar disorder, and 25% an anxiety disorder, as the primary diagnosis. Around 50 patients are seen as new referrals each year.

Anyone interested in graduate studentships or post-doctoral positions (clinical) within the Mental Health Group are encouraged to contact Professor Baldwin directly.

Academic unit:  Clinical and Experimental Sciences Academic Units

Affiliate academic units:  Clinical Neuroscience Research group

Responsibilities

Postgraduate student supervision
  • 2013 Ben Ainsworth PhD
  • 2012 David Bartram PhD
  • 2007 Pippa Biswas DM
  • 2006 Andrew Mayers PhD

Current

  • Daniel Meron DM
  • Nupur Tiwari DM
  • Louise Baker PhD
  • Hesham Elnazer DM
  • Michael Breen PhD
  • Conal Twomey PhD
  • Verity Pinkney PhD
  • Joanna Miler PhD
  • Claire Bakhtiar PhD


Faculty of Medicine

Head of Mental Health Group
Deputy Director of Clinical Neuroscience and Psychiatry Academic Sub-Unit

National and international responsibilities

Editor of Human Psychopharmacology
Responsible for liaison between the ECNP and European Medicines Agency
Medical Patron of the Anxiety UK
Past President of Depression Alliance
Vice Chair of the MOD Research Ethics Committee

Teaching Responsibilities

BM5. Delivers lectures in Year 2 and seminars in Year 3.

BMedSci. Offers up to 4 project placements (joint supervision) in area of mood and anxiety disorders.

BSc Biomedical Science. ‘Masterclass’ on affective disorders.

Personal tutor for students throughout BM4, BM5 and BM6 curricula.

Contact

Professor David Baldwin
University Department of Psychiatry
Academic Centre, College Keep
4-12 Terminus Terrace
Southampton SO14 3DT

Phone: +44 (0) 23 8071 8520
Fax: +44 (0) 23 8071 8532
Email: dsb1@soton.ac.uk

Room Number: College Keep/22